Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
Globe Newswire•18/10/2026•17:00 ET
0
Key Highlights
- ➤Disc Medicine (IRON) will discuss APOLLO Phase 3 bitopertin topline results October 19, 2026
- ➤Corporate webcast scheduled for 8:00 a.m. ET Monday
- ➤Bitopertin remains investigational and is not approved worldwide
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET.
Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com. A replay of the webcast will be made available on the website following the call.
Get started
Create a free account to read the full story.